Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of long-term
administration of etanercept in adults with psoriasis who have participated in previous
etanercept psoriasis studies. This study will also evaluate the maintenance of the efficacy
of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis
studies. All subjects enrolled in this study will receive 50 mg once weekly or twice weekly
(if qualified after week 12) by subcutaneous injections for at least 48 weeks and up to 72
weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Collaborators:
Immunex Corporation Wyeth is now a wholly owned subsidiary of Pfizer